Can a 77-Year-Old Male on Aspirin, Diazepam, and Telmisartan Safely Take Paxlovid for COVID-19?
Yes, this patient can take Paxlovid, but diazepam must be temporarily discontinued during the 5-day treatment course due to a potentially dangerous drug interaction with ritonavir. Aspirin and telmisartan can be safely continued.
Critical Drug Interaction Assessment
Diazepam - REQUIRES DISCONTINUATION
The ritonavir component of Paxlovid is a strong CYP3A inhibitor that will significantly increase diazepam levels, potentially causing excessive sedation, respiratory depression, and prolonged benzodiazepine effects 1. Hold diazepam for the entire 5-day Paxlovid course and for 2-3 days after completion to allow ritonavir clearance. Consider short-term alternatives for anxiety/insomnia if needed (e.g., low-dose trazodone), but avoid other benzodiazepines.
Aspirin - SAFE TO CONTINUE
Aspirin has no significant interaction with Paxlovid and should be continued unchanged, particularly if prescribed for cardiovascular protection 2. Patients with COVID-19 on antiplatelet therapy for underlying cardiovascular conditions should continue this treatment unless significant bleeding develops 2.
Telmisartan - SAFE TO CONTINUE
Angiotensin receptor blockers like telmisartan do not interact with Paxlovid and should be continued 3. Large studies demonstrate no increased risk of adverse outcomes when continuing ARBs during COVID-19 treatment.
Paxlovid Dosing Considerations for This Patient
Age-Related Factors
At 77 years old, this patient is in the high-risk category where Paxlovid demonstrates substantial benefit 4, 5, 6. Real-world data show Paxlovid reduces hospitalization risk by 39% and death by 61%, with particularly strong effects in patients ≥65 years 6.
Renal Function Assessment - CRITICAL
You must check this patient's estimated glomerular filtration rate (eGFR) before prescribing 1:
- eGFR ≥60 mL/min: Standard dose (300 mg nirmatrelvir + 100 mg ritonavir twice daily)
- eGFR 30-59 mL/min: Reduced dose (150 mg nirmatrelvir + 100 mg ritonavir twice daily)
- eGFR <30 mL/min: Paxlovid NOT recommended
Timing Requirements
Initiate Paxlovid within 5 days of symptom onset for maximum effectiveness 4, 1, 5. The full 5-day course must be completed even if symptoms improve.
Practical Management Algorithm
- Immediately check renal function (eGFR) to determine appropriate Paxlovid dosing
- Discontinue diazepam before starting Paxlovid; counsel patient on temporary withdrawal
- Continue aspirin and telmisartan at current doses
- Prescribe appropriate Paxlovid dose pack based on renal function
- Monitor for benzodiazepine withdrawal symptoms during the 5-7 day period off diazepam
- Resume diazepam 2-3 days after completing Paxlovid course
Common Pitfalls to Avoid
Do not assume all medications are safe to continue - the ritonavir component creates numerous drug interactions through CYP3A inhibition 1, 7. The FDA boxed warning specifically emphasizes reviewing ALL medications before prescribing.
Do not restart diazepam immediately after the last Paxlovid dose - ritonavir has a half-life requiring 2-3 days for adequate clearance to avoid prolonged drug interaction 8.
Do not prescribe standard dosing without checking renal function - elderly patients frequently have reduced kidney function requiring dose adjustment 1, 9.
Additional Safety Considerations
Monitor for hypersensitivity reactions (rash, angioedema, difficulty breathing) particularly after the first dose 1. Instruct the patient to discontinue Paxlovid and seek immediate care if these occur.
The combination of advanced age, multiple comorbidities (implied by aspirin use), and COVID-19 places this patient at high risk for severe disease progression, making Paxlovid treatment strongly indicated despite the need for medication adjustments 4, 5, 6.